IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kumar, S.
Right arrow Articles by Kaslow, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kumar, S.
Right arrow Articles by Kaslow, D. C.

 Previous Article  |  Next Article 

Infection and Immunity, April 2000, p. 2215-2223, Vol. 68, No. 4
0019-9567/00/$04.00+0

Immunogenicity and Efficacy in Aotus Monkeys of Four Recombinant Plasmodium falciparum Vaccines in Multiple Adjuvant Formulations Based on the 19-Kilodalton C Terminus of Merozoite Surface Protein 1

Sanjai Kumar,1,* William Collins,2 Andrea Egan,1 Anjali Yadava,1 Olivier Garraud,1 Michael J. Blackman,3 Jose A. Guevara Patino,3 Carter Diggs,4 and David C. Kaslow1

Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, Maryland 208921; Division of Parasitic Diseases and Scientific Resources Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 303332; Division of Parasitology, National Institute for Medical Research, London NW71AA, United Kingdom3; Malaria Vaccine Development Program, U.S. Agency for International Development, Washington, D.C. 205234

Received 20 October 1999/Returned for modification 6 December 1999/Accepted 12 January 2000

The immunogenicity and protective efficacy of four versions of recombinant C-terminal 19-kDa epidermal growth factor-like region of the major surface protein 1 (rMSP119) of Plasmodium falciparum was studied in Aotus monkeys. Vaccination with each of the four rMSP119 constructs elicited high levels of antibodies to MSP119 but only one construct, the 19-kDa fragment expressed as a secreted fusion protein from Saccharomyces cerevisiae (yP30P2MSP119), induced a high degree of protective immunity in Aotus nancymai against lethal P. falciparum challenge. Protective formulation required Freund's adjuvant; vaccination with yP30P2MSP119 in six other adjuvants that are suitable for human use induced lower levels of antibody response and no protection. These results emphasize the need to continue the search for an adjuvant that is comparable to Freund's adjuvant in potency and is safe for use in humans.


* Corresponding author. Present address: Malaria Program, Naval Medical Research Center, 503 Robert Grant Ave., Silver Spring, MD 20910-7500. E-mail: kumars{at}nmripo.nmri.nnmc.navy.mil.


Infection and Immunity, April 2000, p. 2215-2223, Vol. 68, No. 4
0019-9567/00/$04.00+0



This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals

Copyright © 2000 by the American Society for Microbiology. All rights reserved.